These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 35044127)

  • 1. [Independence of ischemic stroke patients after alteplase systemic thrombolytic therapy].
    Belkina SN; Kotov SV; Isakova EV; Kotov AS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(12. Vyp. 2):56-61. PubMed ID: 35044127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Intravenous thrombolytic therapy of ischemic stroke with the drug Revelisa in real clinical practice: results of the IVT-AIS-R study].
    Soldatov MA; Klimov LV; Tolmachev AP; Kiseleva TV; Androfagina OV; Beketova EM; Belkina SN; Borisov DN; Karpov DY; Krasyuk MS; Kucheryavaya MV; Minina YD; Novikov DG; Rogozhnikova NV; Tabakman SV; Teliatnik YA; Tretyakov KV; Fadeeva AS; Khan DS; Chirkov AN; Marskaya NA; Shamalov NA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(12. Vyp. 2):42-49. PubMed ID: 36582160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Intravenous thrombolytic therapy with Revelisa of ischemic stroke in real-world clinical practice: interim results of an open-label, prospective, multicenter, non-interventional study IVT-AIS-R].
    Soldatov MA; Marskaya NA; Barsegova KA; Androfagina OV; Borisov DN; Karpov DY; Kishinevsky MV; Kucheryavaya MV; Tabakman SV; Telyatnik YA; Fadeeva AS; Khan DS; Chirkov AN; Shamalov NA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(3. Vyp. 2):33-37. PubMed ID: 33908230
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparative characteristics of the efficacy and safety of the original alteplase and its complete biosimilar in the treatment of ischemic stroke in real clinical practice].
    Marchenko SV; Hil UV; Hil IG
    Zh Nevrol Psikhiatr Im S S Korsakova; 2024; 124(3. Vyp. 2):49-54. PubMed ID: 38512095
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Experience of using a Russian alteplase product as thrombolytic therapy in patients with ischemic stroke in routine practice].
    Murtazalieva DM; Zakaryaeva AR; Soshina TD; Zolotov MA; Parfenov VA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(8. Vyp. 2):55-59. PubMed ID: 37682096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased benefit of alteplase in patients with ischemic stroke and a high body temperature.
    de Ridder I; den Hertog H; van Gemert M; Dippel D; van der Worp B;
    Cerebrovasc Dis; 2013; 35(1):60-3. PubMed ID: 23428998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multicenter Study of Intravenous Recombinant Tissue Plasminogen Activator Infusion around Hiroshima, Japan: The Hiroshima Acute Stroke Retrospective and Prospective Registry Study.
    Aoki S; Hosomi N; Sueda Y; Kono T; Takamatsu K; Ohyama H; Torii T; Kitamura T; Nomura E; Noda K; Ohtsuki T; Matsumoto M;
    J Stroke Cerebrovasc Dis; 2015 Dec; 24(12):2747-53. PubMed ID: 26360972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transcranial Pulsed Ultrasound with Alteplase Intravenous Thrombolysis for Vascular Recanalisation in Acute Ischemic Stroke.
    Chen Z; Zhang J
    J Coll Physicians Surg Pak; 2020 Jul; 30(7):765-767. PubMed ID: 32811613
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.
    Clark WM; Wissman S; Albers GW; Jhamandas JH; Madden KP; Hamilton S
    JAMA; 1999 Dec; 282(21):2019-26. PubMed ID: 10591384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of thrombolytic agents in treatment of patients with acute ischemic stroke; findings from a single centre follow up study in real-life settings.
    George M; Baby N; Paul R; Zabeer M; Thomas C
    J Clin Neurosci; 2021 Sep; 91():299-305. PubMed ID: 34373043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and safety of non-immunogenic staphylokinase in the ischemic stroke in real-world clinical practice in the Sverdlovsk region].
    Alasheev AM; Lantsova EV; Tretyakov DA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2023; 123(7):74-79. PubMed ID: 37490668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan Alteplase Clinical Trial (J-ACT).
    Yamaguchi T; Mori E; Minematsu K; Nakagawara J; Hashi K; Saito I; Shinohara Y;
    Stroke; 2006 Jul; 37(7):1810-5. PubMed ID: 16763187
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tenecteplase versus alteplase after acute ischemic stroke at high age.
    Thommessen B; Næss H; Logallo N; Kvistad CE; Waje-Andreassen U; Ihle-Hansen H; Ihle-Hansen H; Thomassen L; Morten Rønning O
    Int J Stroke; 2021 Apr; 16(3):295-299. PubMed ID: 32631157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thromboelastographic changes in patients experiencing an acute ischemic stroke and receiving alteplase.
    Rowe AS; Greene CL; Snider CC; Carroll RC; Wiseman BF; Henry JM; Langdon JR; Craft RM
    J Stroke Cerebrovasc Dis; 2014 Jul; 23(6):1307-11. PubMed ID: 24439128
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Off-label thrombolysis versus full adherence to the current European Alteplase license: impact on early clinical outcomes after acute ischemic stroke.
    Cappellari M; Moretto G; Micheletti N; Donato F; Tomelleri G; Gulli G; Carletti M; Squintani GM; Zanoni T; Ottaviani S; Romito S; Tommasi G; Musso AM; Deotto L; Gambina G; Zimatore DS; Bovi P
    J Thromb Thrombolysis; 2014 May; 37(4):549-56. PubMed ID: 23943338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and Preliminary Efficacy of Early Tirofiban Treatment After Alteplase in Acute Ischemic Stroke Patients.
    Li W; Lin L; Zhang M; Wu Y; Liu C; Li X; Huang S; Liang C; Wang Y; Chen J; Feng W
    Stroke; 2016 Oct; 47(10):2649-51. PubMed ID: 27608821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Community-based thrombolytic therapy of acute ischemic stroke in Helsinki.
    Lindsberg PJ; Soinne L; Roine RO; Salonen O; Tatlisumak T; Kallela M; Häppölä O; Tiainen M; Haapaniemi E; Kuisma M; Kaste M
    Stroke; 2003 Jun; 34(6):1443-9. PubMed ID: 12738891
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Tirofiban Administered at Different Time Points after Intravenous Thrombolytic Therapy with Alteplase in Patients with Acute Ischemic Stroke.
    Liu J; Shi Q; Sun Y; He J; Yang B; Zhang C; Guo R
    J Stroke Cerebrovasc Dis; 2019 Apr; 28(4):1126-1132. PubMed ID: 30655038
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Even Faster Door-to-Alteplase Times and Associated Outcomes in Acute Ischemic Stroke.
    Jung S; Rosini JM; Nomura JT; Caplan RJ; Raser-Schramm J
    J Stroke Cerebrovasc Dis; 2019 Dec; 28(12):104329. PubMed ID: 31607439
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of Corticospinal Tract Lesion for Predicting Outcome in Small Perfusion Stroke.
    Zhou Y; Zhang R; Yan S; Zhang M; Chen Z; Hu H; Zhang M; Bivard A; Lin L; Parsons MW; Lou M
    Stroke; 2018 Nov; 49(11):2683-2691. PubMed ID: 30355191
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.